KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial. PMID 40315385 · Ann Am Thorac Soc · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model. PMID 40289279 · Br J Clin Pharmacol · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. PMID 40287313 · Nutr Metab Cardiovasc Dis · 2025-Sep The study is a randomized controlled trial of semaglutide in type 2 diabetes patients, evaluating liver fat change via CT. It is not an oncology study and does not report a time-to-event efficacy endpoint for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of low-dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double-blind, multicenter phase 3 trial. PMID 40251695 · Lipids · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients? PMID 40221951 · Clin Transl Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. PMID 40210090 · Chest · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Endoscopic balloon dilation with steroid injection versus radial incision and cutting with steroid injection for refractory esophageal anastomotic stricture: a randomized study. PMID 40199498 · Endoscopy · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). PMID 40185318 · Am Heart J · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. PMID 40154623 · J Hepatol · 2025-Sep 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. PMID 40107501 · Ophthalmol Retina · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early Intra-articular Hyaluronic Acid Injection After Anterior Cruciate Ligament Reconstruction Provides Short-Term Pain Relief and Improves Early Postoperative Function With No Clinical Benefits at 6 and 12 Months: A Randomized Controlled Trial. PMID 39983793 · Arthroscopy · 2025-Sep The study is a Level I randomized controlled trial in orthopedic surgery (anterior cruciate ligament reconstruction) with a hyaluronic acid intervention. It is not oncology, does not study a malignant neoplasm, and the primary efficacy endpoints are clinical function scores (Lysholm, IKDC) and pain scores (VAS), not time-to-event outcomes (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Carotid Artery Stenting during Endovascular treatment of acute ischemic Stroke (CASES) study protocol for a multicenter randomized clinical trial. PMID 39957001 · Eur Stroke J · 2025-Sep 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Optimizing Reversal of Muscle Relaxation with Sugammadex to Accelerate Discharge Readiness in Operative Laryngoscopy: A Randomized Clinical Trial. PMID 36594162 · Ear Nose Throat J · 2025-Sep The study is a randomized, single-blind clinical trial in anesthesiology evaluating sugammadex for reversal of neuromuscular blockade, with discharge readiness as a key outcome. It is not an oncology study, and the primary endpoint (time to extubation) and secondary endpoints do not meet the required time-to-event efficacy criteria for malignant neoplasms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety and cost-effectiveness of chemo-immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated systematic review and cost-effectiveness analysis. PMID 41234878 · Transl Cancer Res · 2025-Oct-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers. PMID 41234598 · Transl Lung Cancer Res · 2025-Oct-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review. PMID 41234589 · Transl Lung Cancer Res · 2025-Oct-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Take the reins: a study protocol of a randomized controlled trial testing the effects of time-restricted eating vs. nutrition control on cancer-related fatigue among survivors of hematological malignancies. PMID 41174725 · BMC Nutr · 2025-Oct-31 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. PMID 41173494 · J Immunother Cancer · 2025-Oct-31 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
Real-World Evidence: A Randomized, Controlled, Single-Blinded Trial Comparing Oral Sulfate Tablets Versus PEG Formulations for Bowel Preparation Before Colonoscopy. PMID 42425913 · J Clin Gastroenterol · 2025-Oct-30 The record describes a randomized, single-blinded non-inferiority trial of bowel preparation formulations (oral sulfate tablets vs. PEG) for colonoscopy in patients needing screening/surveillance for colorectal cancer. The study's primary endpoints are cleansing efficacy (scored by an FDA scale), tolerability, and adverse events. It does not have an oncology-specific Phase III/IIIb or Phase II/III design, a drug-containing intervention for treating a malignant neoplasm, or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial. PMID 41189486 · BJS Open · 2025-Oct-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Investigation of an integrated standardised pain assessment and management tool in addition to usual care versus usual care alone in oncology outpatient clinics for adults with pain: the CAPTURE cluster randomised pilot trial protocol. ISRCRN86926298. PMID 41168902 · Pilot Feasibility Stud · 2025-Oct-30 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol. PMID 41168808 · Addict Sci Clin Pract · 2025-Oct-30 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO). PMID 41168707 · BMC Cancer · 2025-Oct-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
European Study of Prostate Cancer Screening - 23-Year Follow-up. PMID 41160819 · N Engl J Med · 2025-Oct-30 This is a randomized trial of prostate cancer screening with PSA testing, not a drug intervention. The primary endpoint is prostate cancer mortality (a time-to-event outcome), and it reports original long-term results. However, it is not a drug-containing trial, and the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4. PMID 41052284 · Eur J Endocrinol · 2025-Oct-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. PMID 40923797 · N Engl J Med · 2025-Oct-30 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. PMID 40737596 · Blood · 2025-Oct-30 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 8 Panel · risk unclear
A digital twin methodology using real patient data for sample size reduction in Alzheimer's disease randomized controlled clinical trials. PMID 41282905 · medRxiv · 2025-Oct-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years. PMID 41228275 · Cancers (Basel) · 2025-Oct-29 The record describes a pre-planned subgroup analysis of a Phase III randomized trial, not the primary result report for the entire trial population.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). PMID 41224473 · BMJ · 2025-Oct-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study. PMID 41163129 · Eur J Med Res · 2025-Oct-29 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 4 Panel · risk visible
Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients. PMID 41162545 · Sci Rep · 2025-Oct-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Narrative and cognitive behavioral therapy improve psychosocial and oncologic outcomes after abdominoperineal resection: a randomized controlled trial. PMID 41160369 · J Cancer Surviv · 2025-Oct-29 Eligibility excluded due to lack of a drug-containing intervention and unclear trial phase (not confirmed as Phase III/IIIb or Phase II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer. PMID 41295472 · Vaccines (Basel) · 2025-Oct-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Serum CA19-9 and CEA levels, serum CAT, GSH, oxidised glutathione levels, 8-dihidro-2'-deoksiguanosina and F2-isoprostanes levels in colorectal cancer patients and Lactobacillus: A randomised double-blind controlled trial. PMID 41281285 · J Med Biochem · 2025-Oct-28 The study is a randomized, placebo-controlled trial in oncology patients, but it does not meet key eligibility criteria: the trial phase is not explicitly identified as Phase III/IIIb or Phase II/III, the intervention is a dietary supplement (Lactobacillus) rather than a drug, and the endpoints are biomarkers of oxidative stress and signaling pathways, not time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery. PMID 41152991 · Trials · 2025-Oct-28 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PMID 41152774 · BMC Cancer · 2025-Oct-28 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial. PMID 41151963 · BMJ Open · 2025-Oct-28 While the record describes a phase 3 randomized trial in oncology with a drug intervention, the primary and reported outcomes are participant experience and satisfaction measures (quality-of-life domain), not a primary/key secondary time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the cohort's inclusion criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Milrinone infusion for vasospasm treatment in subarachnoid haemorrhage: protocol for a double-blind randomised clinical trial - the MiVAR study. PMID 41151960 · BMJ Open · 2025-Oct-28 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial. PMID 41026481 · JAMA · 2025-Oct-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. PMID 40706052 · Blood Adv · 2025-Oct-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. PMID 40590852 · Blood Adv · 2025-Oct-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Correction to: Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study. PMID 38801299 · Mod Rheumatol · 2025-Oct-28 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evolving Resection Strategies for Non-Small Cell Lung Cancers: Translating Trial Evidence to Real-World Practice. PMID 41228230 · Cancers (Basel) · 2025-Oct-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Improving physiotherapists' ability to recognise the presence of a serious pathology with a digital educational training: a mixed methods feasibility study. PMID 41146172 · BMC Med Educ · 2025-Oct-27 The record describes a mixed-methods feasibility study of a digital educational training for physiotherapists to improve recognition of serious pathologies (including cancer). It is not a clinical trial of a cancer drug, does not have a time-to-event efficacy endpoint, and is not a Phase II/III or Phase III randomized controlled trial of a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Advancing Knowledge of Values-Clarification Processes During Complex Decision-Making Among Older Adults With Advanced Cancer: Protocol for a Pilot Randomized Trial Using Simulated Patient-Clinician Encounters. PMID 41144958 · JMIR Res Protoc · 2025-Oct-27 This is a protocol for a pilot randomized trial focusing on shared decision-making processes and quality-of-life considerations. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. PMID 41144077 · J Gastrointest Cancer · 2025-Oct-27 The record is a randomized, prospective, human oncology trial with time-to-event endpoints and drug intervention, but the abstract does not explicitly state the trial phase (e.g., Phase II or III). Metadata cannot confirm the required phase criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Electroacupuncture for chemotherapy-induced gastrointestinal symptoms in colorectal cancer: protocol for a multicenter, three-arm, randomized controlled trial. PMID 41144022 · Int J Colorectal Dis · 2025-Oct-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Synergistic Effects of Microencapsulated Polyphenols and Concurrent Training on Metabolic Health and Fitness in Overweight/Obese Adults with Prediabetes. PMID 41228432 · Nutrients · 2025-Oct-25 The study is a randomized, placebo-controlled trial in humans with a drug intervention (polyphenol supplement) and original primary results. However, it is not an oncology study (focused on prediabetes/metabolic health), does not specify a Phase III or definitive Phase II/III trial phase, and lacks any time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the eligibility criteria for this oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Focal Therapy Using High-Intensity Focused Ultrasound for Low- and Intermediate-Risk Prostate Cancer: Results from a Prospective, Multicenter Feasibility Trial. PMID 41228223 · Cancers (Basel) · 2025-Oct-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -